Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Harvard Business School
McKinsey
Baxter
Express Scripts

Last Updated: October 22, 2019

DrugPatentWatch Database Preview

APTIVUS Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Aptivus, and when can generic versions of Aptivus launch?

Aptivus is a drug marketed by Boehringer Ingelheim and is included in two NDAs. There are three patents protecting this drug.

This drug has one hundred and fifty-six patent family members in thirty-one countries.

The generic ingredient in APTIVUS is tipranavir. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the tipranavir profile page.

Drug patent expirations by year for APTIVUS
Drug Prices for APTIVUS

See drug prices for APTIVUS

Generic Entry Opportunity Date for APTIVUS
Generic Entry Dates for APTIVUS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for APTIVUS*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for APTIVUS

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Boehringer IngelheimPhase 3
National Institute of Mental Health (NIMH)Phase 2/Phase 3
National Institutes of Health (NIH)Phase 2/Phase 3

See all APTIVUS clinical trials

Pharmacology for APTIVUS
Drug ClassProtease Inhibitor
Mechanism of ActionHIV Protease Inhibitors
Synonyms for APTIVUS
174484-41-4
1d4y
2-Pyridinesulfonamide, N-(3-((1R)-1-((6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-
2-Pyridinesulfonamide, N-(3-(1-(5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl)propyl)phenyl)-5-(trifluoromethyl)-, (R-(R*,R*))-
2-Pyridinesulfonamide, N-[3-[(1R)-1-[(6R)-5,6-dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-
2o4l
2o4n
2o4p
3'-((1R)-1-((6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-phenethyl-6-propyl-2H-pyran-3-yl)propyl)-5-(trifluoromethyl)-2-pyridinesulfonanilide
A811642
AC1L22FH
AC1Q4JPW
AKOS030254403
AN-5550
Aptivus (Boehringer Ingelheim)
Aptivus (TN)
Aptivus(TM)
C31H33F3N2O5S
CAS-174484-41-4
CHEBI:63628
CHEMBL183041
CHEMBL222559
CS-1210
CTK8E7540
D08605
DB00932
DSSTox_CID_28548
DSSTox_GSID_48622
DSSTox_RID_82820
DTXSID6048622
FT-0675248
HSDB 8083
HY-15148
J-010991
KB-81165
MolPort-003-850-561
N-(3-((R)-1-((R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3,4-dihydro-2H-pyran-5-yl)propyl)phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide
N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide
N-(3-{(1R)-1-[(6R)-4-HYDROXY-2-OXO-6-PHENETHYL-6-PROPYL-5,6-DIHYDRO-2H-PYRAN-3-YL]PROPYL}PHENYL)-5-(TRIFLUOROMETHYL)-2-PYRIDINESULFONAMIDE
N-[3-[(1R)-1-[(2R)-4-hydroxy-6-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
N-[3-[(1R)-1-[(2R)-6-hydroxy-4-oxo-2-phenethyl-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
N-[3-[(1R)-1-[(2R)-6-oxidanyl-4-oxidanylidene-2-(2-phenylethyl)-2-propyl-3H-pyran-5-yl]propyl]phenyl]-5-(trifluoromethyl)pyridine-2-sulfonamide
N-[3-[(1R)-1-[(6R)-5,6-Dihydro-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-2H-pyran-3-yl]propyl]phenyl]-5-(trifluoromethyl)-2-pyridinesulfonamide
N-{3-[(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl]phenyl}-5-(trifluoromethyl)pyridine-2-sulfonamide
NCGC00182028-01
NCGC00379087-01
PNU 140690
PNU-140690
RT-016034
SCHEMBL40629
SCHEMBL40630
Tipranavir
Tipranavir (INN)
Tipranavir [INN:BAN]
tipranavir(pnu-140690,aptivus)
Tox21_112962
TPV
U 140690
U-140690
UNII-ZZT404XD09
W-5247
X2005
ZINC100016058
ZINC100022637
ZZT404XD09

US Patents and Regulatory Information for APTIVUS

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005 RX Yes Yes   Start Trial   Start Trial   Start Trial
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for APTIVUS

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005   Start Trial   Start Trial
Boehringer Ingelheim APTIVUS tipranavir SOLUTION;ORAL 022292-001 Jun 23, 2008   Start Trial   Start Trial
Boehringer Ingelheim APTIVUS tipranavir CAPSULE;ORAL 021814-001 Jun 22, 2005   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Supplementary Protection Certificates for APTIVUS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0758327 PA2005008,C0758327 Lithuania   Start Trial PRODUCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0758327 C300216 Netherlands   Start Trial PRODUCT NAME: TIPRANAVIR, DESGEWENST IN DE VORM VAN EEN; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0758327 PA2005008 Lithuania   Start Trial PRODCT NAME: TIPRANAVIRUM; REGISTRATION NO/DATE: EU/1/05/315/001 20051025
0758327 CA 2005 00052 Denmark   Start Trial
0758327 C00758327/01 Switzerland   Start Trial FORMER REPRESENTANTIVE: E. BLUM AND CO. PATENTANWAELTE, CH
0758327 300216 Netherlands   Start Trial 300216, 20150504, EXPIRES: 20200503
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Mallinckrodt
Medtronic
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.